MiR-106b-5p Promotes Proliferation and Inhibits Apoptosis by Regulating BTG3 in Non-Small Cell Lung Cancer
- PMID: 29197876
- DOI: 10.1159/000485650
MiR-106b-5p Promotes Proliferation and Inhibits Apoptosis by Regulating BTG3 in Non-Small Cell Lung Cancer
Abstract
Background/aims: MicroRNAs have been validated to play a crucial role in tumorigenesis of non-small cell lung cancer (NSCLC). Although miR-106b-5p has been reported to play a vital role in various malignancies the physiological function of miR-106b-5p in NSCLC still remain unknown. In this study, we investigated the role of miR-106b-5p in NSCLC.
Methods: Quantitative real-time polymerase chain reaction was conducted to estimate the expression of miR-106b-5p and BTG3 in both NSCLC tissues and cell lines. The effects of miR-106b-5p on proliferation were determined in vitro using CCK-8 proliferation assays, 5-ethynyl-2'-deoxyuridine (EdU) incorporation, colony formation assays and cell-cycle assays and the in vivo effects were evaluated by a mouse tumorigenicity model. Cell apoptosis and cell cycle was investigated by flow cytometric analysis in vitro. The molecular mechanism underlying the relevance between miR-106b-5p and BTG3 was confirmed by luciferase assay and western blot.
Results: In current study, we found a relatively higher miR-106b-5p and lower BTG3 expression in NSCLC specimens and cell lines. BTG3 was verified as a direct target of miR-106b-5p by luciferase assay. In vitro, over-expression of miR-106b-5p promoted proliferation and inhibited apoptosis by down-regulating BTG3 expression. In vivo, miR-106b-5p promoted xenograft tumor formation.
Conclusion: Our findings revealed for the first time that miR-106b-5p plays a tumorigenesis role in NSCLC progression by down-regulating BTG3 expression, which may lead to a novel insight to the potential biomarker and novel therapeutic strategies for NSCLC patients.
Keywords: Apoptosis; BTG3; Microrna-106b-5p; Non-small-cell lung cancer; Proliferation.
© 2017 The Author(s). Published by S. Karger AG, Basel.
Similar articles
-
MiR-142-5p Suppresses Tumorigenesis by Targeting PIK3CA in Non-Small Cell Lung Cancer.Cell Physiol Biochem. 2017;43(6):2505-2515. doi: 10.1159/000484459. Epub 2017 Oct 31. Cell Physiol Biochem. 2017. PMID: 29131028
-
Inhibition of MicroRNA-21-5p Promotes the Radiation Sensitivity of Non-Small Cell Lung Cancer Through HMSH2.Cell Physiol Biochem. 2017;43(3):1258-1272. doi: 10.1159/000481839. Epub 2017 Oct 9. Cell Physiol Biochem. 2017. Retraction in: Cell Physiol Biochem. 2021;55(5):665. doi: 10.33594/000000455. PMID: 29024929 Retracted.
-
The Long Non-Coding RNA XIST Controls Non-Small Cell Lung Cancer Proliferation and Invasion by Modulating miR-186-5p.Cell Physiol Biochem. 2017;41(6):2221-2229. doi: 10.1159/000475637. Epub 2017 Apr 25. Cell Physiol Biochem. 2017. PMID: 28448993
-
MiRNA-106b-5p in human cancers: diverse functions and promising biomarker.Biomed Pharmacother. 2020 Jul;127:110211. doi: 10.1016/j.biopha.2020.110211. Epub 2020 May 4. Biomed Pharmacother. 2020. PMID: 32422566 Review.
-
miR-106b as an emerging therapeutic target in cancer.Genes Dis. 2021 Feb 12;9(4):889-899. doi: 10.1016/j.gendis.2021.02.002. eCollection 2022 Jul. Genes Dis. 2021. PMID: 35685464 Free PMC article. Review.
Cited by
-
MicroRNA-106b-5p promotes hepatocellular carcinoma development via modulating FOG2.Onco Targets Ther. 2019 Jul 15;12:5639-5647. doi: 10.2147/OTT.S203382. eCollection 2019. Onco Targets Ther. 2019. PMID: 31406464 Free PMC article.
-
miR-140-3p inhibits progression of non-small cell lung cancer by targeting Janus kinase 1.J Biosci. 2020;45:48. J Biosci. 2020. PMID: 32345774
-
LGP2 virus sensor regulates gene expression network mediated by TRBP-bound microRNAs.Nucleic Acids Res. 2018 Sep 28;46(17):9134-9147. doi: 10.1093/nar/gky575. Nucleic Acids Res. 2018. PMID: 29939295 Free PMC article.
-
Serum Exosomes and Their miRNA Load-A Potential Biomarker of Lung Cancer.Cancers (Basel). 2021 Mar 18;13(6):1373. doi: 10.3390/cancers13061373. Cancers (Basel). 2021. PMID: 33803617 Free PMC article. Review.
-
Altered expression of microRNAs and B lymphocytes during Natalizumab therapy in multiple sclerosis.Heliyon. 2021 Jun 9;7(6):e07263. doi: 10.1016/j.heliyon.2021.e07263. eCollection 2021 Jun. Heliyon. 2021. PMID: 34179535 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical